恒瑞和凯莱拉报告说,口服瑞巴在肥胖的中国成年人中减肥的结果很有希望,为第三期试验铺平了道路. Hengrui and Kailera report promising weight loss results with oral ribupatide in Chinese adults with obesity, paving the way for Phase 3 trials.

Hengrui Pharma和Kailera治疗学报告称,中国成人肥胖症患者口服性硬化剂(一种针对GLP-1和GIP受体的一次性避孕药)的口服性硬化剂(Ripupatide)第二阶段试验结果良好。 Hengrui Pharma and Kailera Therapeutics report positive Phase 2 trial results for oral ribupatide, a once-daily pill targeting GLP-1 and GIP receptors, in adults with obesity in China. 参与者在26周内服用25毫克或50毫克剂量,体重损失高达12.1%,而安慰剂组为2.3%。 没有观察到高原。 Participants taking 25 mg or 50 mg doses lost up to 12.1% of body weight over 26 weeks, compared to 2.3% in the placebo group, with no plateau observed. 在25毫克剂量下,59.1%至少损失10%,38.6%损失15%或以上。 At the 25 mg dose, 59.1% lost at least 10% and 38.6% lost 15% or more. 肠胃副作用很普遍,但大多是轻微的,没有停止治疗。 Gastrointestinal side effects were common but mostly mild, with no treatment discontinuations. 这些公司计划在中国将口服配方推进到第三阶段试验,并继续在全球开发注射版。 The companies plan to advance the oral formulation into Phase 3 trials in China and continue global development of the injectable version.